Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations

First‐in‐Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer

(2019) Aiwu Ruth He et al.   ONCOLOGIST

Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation

(2019) Sabrina Baltschukat et al.   CLINICAL CANCER RESEARCH

Case report: HER2 amplification as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping

(2019) Guanggui Ding et al.   CANCER BIOLOGY & THERAPY

Preclinical pharmacokinetics, disposition, and translational pharmacokinetic/pharmacodynamic modeling of savolitinib, a novel selective cMet inhibitor

(2019) Yi Gu et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping

(2019) Wei Jin et al.   Journal of Thoracic Oncology

Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro

(2019) Toshio Fujino et al.   Journal of Thoracic Oncology

Co-occurring alterations in the RAS-MAPK pathway limit response to MET inhibitor treatment in MET exon 14 skipping mutation-positive lung cancer

(2019) Julia K Rotow et al.   CLINICAL CANCER RESEARCH

Response and acquired resistance to savolitinib in a patient with pulmonary sarcomatoid carcinoma harboring MET exon 14 skipping mutation: a case report

(2019) Sen Han et al.   OncoTargets and Therapy

MA09.11 Mechanisms of Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14 Mutant Non-Small Cell Lung Cancer

(2019) G. Recondo et al.   Journal of Thoracic Oncology

MA03.09 Dramatic Responses to Immune Checkpoint Inhibitors in MET Exon 14 Skipping Mutation (METex14mut) Non Small Cell Lung Cancers

(2019) M. Mayenga et al.   Journal of Thoracic Oncology

Distinct MET Protein Localization Associated With MET Exon 14 Mutation Types in Patients With Non–small-cell Lung Cancer

(2018) Tian Qiu et al.   Clinical Lung Cancer

Novel MET Exon 14 Skipping Treatment-Naïve Lung Adenocarcinoma Presented Primary Resistance to Crizotinib

(2018) Wenjuan Jiang et al.   Journal of Thoracic Oncology

PD-L1 Expression, Tumor Mutational Burden, and Response to Immunotherapy in Patients with MET exon 14 Altered Lung Cancers

(2018) J K Sabari et al.   ANNALS OF ONCOLOGY

Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung Cancer

(2018) Ken Suzawa et al.   CLINICAL CANCER RESEARCH

Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation

(2018) Julia K. Rotow et al.   Clinical Lung Cancer

MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping

(2017) S. Betty Yan et al.   INVESTIGATIONAL NEW DRUGS

Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping

(2017) Sai-Hong Ignatius Ou et al.   Journal of Thoracic Oncology

Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

(2017) Alexander Drilon et al.   Journal of Thoracic Oncology

P2.06-017 Amethyst NSCLC Trial: Phase 2 Study of MGCD265 in Patients with Advanced or Metastatic NSCLC with Activating Genetic Alterations in MET

(2017) Lyudmila Bazhenova et al.   Journal of Thoracic Oncology

Mutation of MET Y1230 as an Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping

(2017) Alexa B. Schrock et al.   Journal of Thoracic Oncology

Intracranial Activity of Cabozantinib in MET Exon 14–Positive NSCLC with Brain Metastases

(2017) Samuel J. Klempner et al.   Journal of Thoracic Oncology

MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values

(2017) Geun Dong Lee et al.   Journal of Thoracic Oncology

Acquired resistance to crizotinib in advanced lung adenocarcinoma with MET exon 14 skipping

(2017) Yu Zhang et al.   LUNG CANCER

A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population

(2017) Chien-Hung Gow et al.   LUNG CANCER

MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics

(2017) Dohee Kwon et al.   LUNG CANCER

The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable

(2017) Thanyanan Reungwetwattana et al.   LUNG CANCER

MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung

(2017) Raphaël Saffroy et al.   Oncotarget

Gene aberrations for precision medicine against lung adenocarcinoma

(2016) Motonobu Saito et al.   CANCER SCIENCE

MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis

(2016) J. H. Tong et al.   CLINICAL CANCER RESEARCH

MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression

(2016) Mark M. Awad et al.   JOURNAL OF CLINICAL ONCOLOGY

Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations

(2016) Xuewen Liu et al.   JOURNAL OF CLINICAL ONCOLOGY

Acquired Resistance to Crizotinib in NSCLC with MET  Exon 14 Skipping

(2016) Rebecca S. Heist et al.   Journal of Thoracic Oncology

The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC

(2016) Si-Yang Liu et al.   Journal of Thoracic Oncology

Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations

(2016) Alexa B. Schrock et al.   Journal of Thoracic Oncology

Response and acquired resistance to crizotinib in Chinese patients with lung adenocarcinomas harboring MET Exon 14 splicing alternations

(2016) Hua-Jie Dong et al.   LUNG CANCER

Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer

(2016) D. Kazandjian et al.   ONCOLOGIST

MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer

(2016) Difan Zheng et al.   Oncotarget

Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping

(2015) P. K. Paik et al.   Cancer Discovery

Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors

(2015) G. M. Frampton et al.   Cancer Discovery

U.S. Food and Drug Administration Approval: Crizotinib for Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer That Is Anaplastic Lymphoma Kinase Positive

(2014) S. M. Malik et al.   CLINICAL CANCER RESEARCH

Comprehensive molecular profiling of lung adenocarcinoma

(2014) Eric A. Collisson et al.   NATURE

Dramatic Antitumor Effects of the Dual MET/RON Small-Molecule Inhibitor LY2801653 in Non-Small Cell Lung Cancer

(2013) I. Kawada et al.   CANCER RESEARCH

Inhibition of Tumor Growth and Metastasis in Non-Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET

(2013) W. Wu et al.   CLINICAL CANCER RESEARCH

Cabozantinib in Progressive Medullary Thyroid Cancer

(2013) Rossella Elisei et al.   JOURNAL OF CLINICAL ONCOLOGY

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models

(2012) S. Betty Yan et al.   INVESTIGATIONAL NEW DRUGS

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

(2011) F. M. Yakes et al.   MOLECULAR CANCER THERAPEUTICS

An overview of the c-MET signaling pathway

(2011) Shawna Leslie Organ et al.   Therapeutic Advances in Medical Oncology

Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers

(2010) Ryoichi Onozato et al.   Journal of Thoracic Oncology